SCHEMBL6306349

SCHEMBL6306349

O=C(N[C@@H]1C[C@H]2CCN(C2)C1)c1ccc(Oc2ccc(Cl)o2)cc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 8/20 0.65
USP30 Q70CQ3 2/20 0.41
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MMP13 P45452 2/20 0.38
MMP2 P08253 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
MMP12 P39900 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6306353 1.00 CHRNA7 (0.65) CHRNA7USP30HTR3EHTR3BALOX15
SCHEMBL6305984 0.95 CHRNA7 (0.57) CHRNA7USP30HTR3EHTR3BALOX15
SCHEMBL6306523 0.88 CHRNA7 (0.58) CHRNA7USP30MMP13MMP2MEN1
SCHEMBL6309669 0.88 CHRNA7 (0.58) CHRNA7USP30MMP13MMP2MEN1
SCHEMBL6306529 0.88 CHRNA7 (0.58) CHRNA7USP30MMP13MMP2MEN1
SCHEMBL6309677 0.88 CHRNA7 (0.58) CHRNA7USP30MMP13MMP2MEN1
SCHEMBL6305766 0.85 CHRNA7 (0.55) CHRNA7USP30MMP13
SCHEMBL6305763 0.85 CHRNA7 (0.55) CHRNA7USP30MMP13
SCHEMBL6303396 0.85 CHRNA7 (0.86) CHRNA7USP30HTR3EHTR3BALOX15
SCHEMBL6303394 0.85 CHRNA7 (0.86) CHRNA7USP30HTR3EHTR3BALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852716-B2 Substituted-aryl compounds for treatment of disease PFIZER INC (US) 2005-02-08 US claimed
US-20030236279-A1 Substituted-aryl compounds for treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
US-6852716-B2 Substituted-aryl compounds for treatment of disease PFIZER INC (US) 2005-02-08 US disclosed
US-20030236279-A1 Substituted-aryl compounds for treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236279-A1 Substituted-aryl compounds for treatment of disease NAT1, CYP7A1, CYP7B1 CHRNA7 2937/4885USP30 4046/4885HTR3E 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.